publication . Article . Other literature type . 2016

Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma

Jonas Sokolof; Kate Fife; Rainer Kunstfeld; Rogerio I. Neves; Reinhard Dummer; Aleksandar Sekulic; Scott Ernst; Ketty Peris; Axel Hauschild; Nicole Basset-Seguin; ...
View all 15 authors
Open Access
  • Published: 10 Aug 2016 Journal: The Oncologist, volume 21, pages 1,218-1,229 (issn: 1083-7159, eissn: 1549-490X, Copyright policy)
  • Publisher: Wiley
  • Country: Switzerland
Abstract
Vismodegib and sonidegib are Hedgehog pathway inhibitors (HPIs) approved for treatment of patients with advanced basal cell carcinoma. The adverse events (AEs) associated with these therapies can impact clinical outcomes as a result of decreased quality of life and treatment discontinuation. The incidence, clinical presentation, putative mechanisms, and management strategies for AEs related to administration of HPIs are described in this article.
doi: 10.1634/theoncologist.2016-0186 , 10.5167/uzh-125570
pmc: PMC5061532
View all 4 identifiers
Subjects
free text keywords: Cancer Research, Oncology, 1, 17, Melanoma and Cutaneous Malignancies, Adverse events, Management, Advanced basal cell carcinoma, Hedgehog pathway, Dermatology Clinic, 610 Medicine & health, Biphenyl compound, Vismodegib, medicine.drug, medicine, Surgery, medicine.medical_specialty, Sonidegib, chemistry.chemical_compound, chemistry, Internal medicine, Taste disorder, business.industry, business, Adverse effect, Basal cell carcinoma, medicine.disease, Hedgehog signaling pathway, Dysgeusia, medicine.symptom
Related Organizations
View more
Funded by
NIH| MOUSE GENETICS
Project
MOUSE GENETICS
  • Funder: National Institutes of Health (NIH)
  • Project Code: 2P30CA008748-43
  • Funding stream: NATIONAL CANCER INSTITUTE
, NIH| Genetic Epidermiology of Melanoma
Project
Genetic Epidermiology of Melanoma
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1R01CA083115-01A2
  • Funding stream: NATIONAL CANCER INSTITUTE
Download fromView all 5 versions
The Oncologist
Article
Provider: UnpayWall
Europe PubMed Central
Article . 2016
Provider: PubMed Central
Zurich Open Repository and Archive
Article . 2016
Provider: Zurich Open Repository and Archive
http://dx.doi.org/10.5167/uzh-...
Other literature type . 2016
Provider: Datacite
View more
79 references, page 1 of 6

Macha, MA, Batra, SK, Ganti, AK. Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma. Cancer Manag Res. 2013; 5: 197-203 [OpenAIRE] [PubMed]

Sekulic, A, Mangold, AR, Northfelt, DW. Advanced basal cell carcinoma of the skin: Targeting the hedgehog pathway. Curr Opin Oncol. 2013; 25: 218-223 [OpenAIRE] [PubMed]

Erivedge [package insert]. South San Francisco, CA: Genentech USA, Inc.; 2015.

4 Medicines.co.uk. Erivedge 150 mg hard capsules: Summary of product characteristics. Available at https://http://www.medicines.org.uk/emc/medicine/28107. Accessed April 4, 2016.

Migden, MR, Guminski, A, Gutzmer, R. Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): A multicentre, randomised, double-blind phase 2 trial. Lancet Oncol. 2015; 16: 716-728 [OpenAIRE] [PubMed]

Sekulic, A, Migden, MR, Oro, AE. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366: 2171-2179 [OpenAIRE] [PubMed]

Sekulic, A, Migden, MR, Lewis, K. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol. 2015; 72: 1021-6.e8 [PubMed]

Sekulic, A, Migden, MR, Basset-Seguin, N. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update (30-month) of the pivotal ERIVANCE BCC study. J Clin Oncol. 2014; 32 (suppl): 9013a [OpenAIRE]

Chang, ALS, Solomon, JA, Hainsworth, JD. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014; 70: 60-69 [PubMed]

Lacouture M, Guillen J, Kudchadkar R et al. Management of frequent vismodegib-related adverse events in patients with locally advanced basal cell carcinoma: RegiSONIC Disease Registry Study. Poster presented at the 74th Annual Meeting of the American Academy of Dermatology; March 6, 2016; Washington, DC.

Sofen, H, Gross, KG, Goldberg, LH. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma. J Am Acad Dermatol. 2015; 73: 99-105.e1 [PubMed]

Basset-Seguin, N, Hauschild, A, Grob, J-J. Vismodegib in patients with advanced basal cell carcinoma (STEVIE): A pre-planned interim analysis of an international, open-label trial. Lancet Oncol. 2015; 16: 729-736 [OpenAIRE] [PubMed]

Teperino, R, Aberger, F, Esterbauer, H. Canonical and non-canonical Hedgehog signalling and the control of metabolism. Semin Cell Dev Biol. 2014; 33: 81-92 [OpenAIRE] [PubMed]

Brennan, D, Chen, X, Cheng, L. Noncanonical Hedgehog signaling. Vitam Horm. 2012; 88: 55-72 [OpenAIRE] [PubMed]

Epstein, EH. Basal cell carcinomas: Attack of the hedgehog. Nat Rev Cancer. 2008; 8: 743-754 [OpenAIRE] [PubMed]

79 references, page 1 of 6
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue